Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 3/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24569427 | 1.00 | CRBN (0.33) | CRBNPDE4BPARP1PARP10PARP11 | |
| SCHEMBL24569436 | 0.81 | SLC6A2 (0.37) | CRBNPARP1 | |
| SCHEMBL240349 | 0.77 | — | — | |
| SCHEMBL685633 | 0.77 | — | — | |
| Trifluoroacetic Acid SCHEMBL29888298 | 0.76 | — | — | |
| SCHEMBL28840975 | 0.73 | CRBN (0.35) | CRBNPARP1PARP10PARP11 | |
| SCHEMBL30008978 | 0.72 | CRBN (0.38) | CRBNPDE4BPARP1PARP10PARP11 | |
| SCHEMBL24569753 | 0.72 | CRBN (0.33) | CRBNPARP1PARP10PARP11 | |
| SCHEMBL24569850 | 0.72 | CRBN (0.33) | CRBNPARP1PARP10PARP11 | |
| SCHEMBL13065453 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267137-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |